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Mesenchymal expression of the BMP antagonist NOGGIN during prostate development plays a critical role in pre-natal ventral prostate
development and opposes BMP4-mediated inhibition of cell proliferation during postnatal ductal development. Morphologic examination of
newborn Noggin−/− male fetuses revealed genitourinary anomalies including cryptorchidism, incomplete separation of the hindgut from the
urogenital sinus (UGS), absence of the ventral mesenchymal pad, and a complete loss of ventral prostate (VP) budding. Examination of lobe-
specific marker expression in the E14 Noggin−/− UGS rescued by transplantation under the renal capsule of a male nude mouse confirmed a
complete loss of VP determination. More modest effects were observed in the other lobes, including decreased number of ductal buds in the dorsal
and lateral prostates of newborn Noggin−/− males. BMP4 and BMP7 have been shown to inhibit ductal budding and outgrowth by negatively
regulating epithelial cell proliferation. We show here that NOGGIN can neutralize budding inhibition by BMP4 and rescues branching
morphogenesis of BMP4-exposed UGS in organ culture and show that the effects of BMP4 and NOGGIN activities converge on P63+ epithelial
cells located at nascent duct tips. Together, these studies show that the BMP–NOGGIN axis regulates patterning of the ventral prostate, regulates
ductal budding, and controls proliferation of P63+ epithelial cells in the nascent ducts of developing mouse prostate.
Published by Elsevier Inc.Keywords: Urogenital sinus; Development; Noggin; Bmp; ProstateIntroduction
The mouse prostate is a male accessory sex organ
comprised of three distinct lobes: The coagulating gland
(CG, also known as the anterior prostate), dorsolateral prostate
(DLP), and ventral prostate (VP). The prostate develops from
the urogenital sinus (UGS), a hindgut derivative of endoder-
mal origin (Staack et al., 2003). The first morphological sign
of prostate development is outgrowth of UGS epithelium into
the surrounding UGS mesenchyme at sites which correspond
to the origin of the three adult prostate lobes (Cunha et al.,⁎ Corresponding author.
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doi:10.1016/j.ydbio.2007.09.0381987). This process, which generates the main ducts of the
adult prostate lobes, is initiated at embryonic day (E)16 in
response to androgen stimulation and depends upon signaling
interactions between UGS epithelial and mesenchymal layers.
A variety of growth and signaling factors play important roles
in prostate ductal budding and differentiation. These factors
include sonic and indian hedgehog (SHH and IHH), fibroblast
growth factor 10 (FGF10), bone morphogenetic proteins
(BMP) 4 and 7, transforming growth factor β, notch1, nk3
homeobox 1, and forkhead box a1. Some of these factors
promote epithelial proliferation and prostatic bud initiation,
elongation, and branching morphogenesis (Almahbobi et al.,
2005; Berman et al., 2004; Doles et al., 2006; Donjacour et
al., 2003; Freestone et al., 2003; Gao et al., 2005; Huang et
al., 2005; Lamm et al., 2002; Pu et al., 2004; Signoretti et al.,
2005; Signoretti et al., 2000; Thomson, 2001; Thomson and
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2004). Others inhibit epithelial cell proliferation and restrict
prostate budding and branching (Grishina et al., 2005; Lamm
et al., 2001). These signaling factors likely exert concerted and
complementary actions to initiate bud initiation and out-
growth. However, significant uncertainty persists about the
mechanisms that regulate the different signaling pathways,
how growth regulation is tied to androgen dependence of
prostatic budding, and how positive and negative growth
signals are choreographed to produce focal growth at the tip of
emerging buds.
Prior to the initiation of prostatic budding, uniform Bmp4
mRNA expression in UGS mesenchyme mirrors expression of
Shh in the UGS epithelium. At the onset of ductal budding,
Bmp4 expression is diminished at the tips of buds while Shh
expression localizes to nascent buds (Lamm et al., 2002, 2001).
Bmp4 expression subsequently diminishes throughout UGS
mesenchyme except for tight rings of expression surrounding
emerging buds. We postulated that down-regulation of BMP4
activity at sites of bud formation provides for localized de-
repression of epithelial proliferation that produces outgrowth of
the bud; however, the mechanisms regulating BMP4 expression
or activity were unclear. More recent studies have shown Bmp7
is expressed in both the mesenchyme and epithelium of the
developing prostate and, like Bmp4, appears to inhibit epithelial
proliferation, ductal budding and branching (Grishina et al.,
2005). The effects of BMP4 and BMP7 on epithelial
proliferation are likely to be a direct effect of the BMP ligands;
however, the genes encoding the type I BMP receptors Bmpr1a
and Bmpr1b are expressed in the mesenchyme as well as in
epithelium, making paracrine mechanisms also possible. Also
like Bmp4, Bmp7 expression decreases in the mesenchyme
adjacent to the duct tip. NOGGIN, a secreted factor which binds
the BMP ligand in extracellular regions and prevents it from
signaling through its receptor (Zimmerman et al., 1996), is
critical for normal organogenesis as evidenced by defects in
neural tube, somite, and skeletal development and lethality of
Noggin−/− mutants (McMahon et al., 1998; Smith, 1999). A
critical role of NOGGIN in opposing and balancing BMP4
activity is demonstrated by a partial rescue of the Noggin−/−
phenotype by Bmp4 haploinsufficiency (Wijgerde et al., 2005).
We report here that the BMP–antagonist Noggin is expressed in
mouse UGS mesenchyme and is required for patterning ventral
prostate development. In addition, we show that NOGGIN
neutralizes inhibition of epithelial proliferation by BMP4 andTable 1
PCR primers for real-time RT-PCR analysis
GenBank accession no. Entrez gene ID For
NM008711 Noggin (Nog) AC
NM007554 Bone morphogenetic protein 4 (Bmp4) AA
NM009170 Sonic hedgehog (Shh) GT
X06246 Microfibrillar-associated protein 5 (Sbp)a AG
U89840 Renin1 (Ren1)a AC
AK137501 Probasin (Pbsn)a AA
NM008907 Peptidylprolyl isomerase A (Ppia)a TC
a From Lin et al. (2003).postulate that the opposing actions of BMP4 and NOGGIN
specify sites of ductal budding and regulate bud outgrowth.
Materials and methods
Tissue collection
CD-1 timed-pregnant mice (Charles River, Willmington, MA) were
euthanized by isoflurane overdose. The day of plug was considered E0. UGS
from E14 to E18 and prostate from postnatal day (P) 1, 5, and 10 male mice were
dissected in Dulbecco's phosphate-buffered saline (PBS). For RT-PCR, UGS
specimens were snap frozen in liquid N2 and stored at −80 °C. For UGS organ
culture, the seminal vesicles and bladder were excised and the UGS was
temporarily stored in ice-cold PBS until culture initiation. For scanning
electronic microscopy, UGS tissue was either stored in 10% FBS in Hank's
Balanced Salt Solution (HBSS) overnight at 4 °C or processed immediately.
RNA isolation and RT-PCR
RNA was isolated from pooled UGS (n=6–9 E14–E18 male fetuses from
multiple litters) or individual prostate tissue from P1 to P10 male neonates.
Specimens were homogenized in Molecular Grinding Resin™ (Genotech, St.
Louis, MO) and tissue homogenates were passed through Qiashredder columns
(Qiagen, Valencia, CA). RNA was extracted from tissue homogenates with the
Qiagen RNeasy kit (Qiagen). Reverse transcription was carried out for 1 h at
42 °C in 1× First stand buffer containing 500 ng total RNA, 0.5 μM dNTPs,
150 ng random hexamers, 5 mM DTT, and 200 U Superscript II Reverse
transcriptase (Invitrogen, Carlsbad, CA). Real-time PCR was performed as
described previously (Lin et al., 2003) using the Roche LightCycler (Roche
Molecular Biochemicals, Indianapolis, IN). PCR primers used in this study are
listed in Table 1.
UGSM-2 cell line
The immortalized UGS mesenchymal clonal cell line (UGSM-2) was
generated from a parent mixed cell population derived from the UGS of an E16
male INK4a−/− transgenic mouse embryo (Shaw et al., 2006). For gain of
function studies, UGSM-2 cells were transfected with a Noggin/GFP bi-citronic
expression vector. Wild-type (WT) UGSM-2 cells (8×106) or UGSM-2 Noggin
overexpressing cells were combined with minced P1 WT prostate tissue,
allowed to recombine overnight in organ culture, and grafted under the renal
capsule for 3 weeks.
Whole-mount in-situ hybridization
UGS and prostate tissue were fixed in 4% paraformaldehyde and hybridized
according to a previously described protocol (Lamm et al., 2001). Briefly,
tissues were bleached for 60 min in 6% H2O2 and digested with 50 μg/ml
proteinase K for 30 min at room temperature. Prehybridization (2 h) and
hybridization (overnight) were each performed at 68 °C. After high stringency
washes, tissues were incubated at 4 °C overnight with pre-blocked alkaline
phosphatase-conjugated anti-digoxigenin. The colorimetric reaction usedward primer Reverse primer
AGCGCCTGAGCAAGAAG AGGTGCACAGACTTGGATGG
TGTGACACGGTGGGAAAC TGGGTGATGCTTGGGACTAC
GGAAGCAGGTTTCGACTG GGTCCAGGAAGGTGAGGAAG
AGCCCAGAATGTCCTGGG TTATCACGTGCTCTCCGTCC
TCGGTGACTGTGGGTGG AGGTGGGAACCCCTGTTGTAG
AGAGAAAGTACAGAGACAGG AATGTACAGCGTATCATGGAC
TCTCCGTAGATGGACCTG ATCACGGCCGATGACGAGCC
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Cryosections were prepared after overnight equilibration in 50% sucrose.
Assay for β-galactosidase activity
β-Galactosidase activity was determined, as an indirect measure of LacZ
expression, by enzymatic cleavage of X-gal (5-bromo-4-chloro-3-indolyl-β-D-
galactoside) as described (Cheng et al., 1993). UGS specimens were fixed for
20 min in ice-cold 4% paraformaldehyde, rinsed with PBS, and suspended in
PBS containing 5 mMK3Fe(CN)3, 5 mMK4Fe(CN)6, 2 mMMgCl2, 0.02% NP-
40, 0.01% sodium deoxycholate, and 1 mg/ml X-gal. Tissues were incubated for
30 min at 37 °C in the dark on a rocking platform, washed with PBS, and imaged
by light microscopy. Cryosections were prepared from these specimens for
further analysis.
In vitro organ culture
E14 UGS or P1 prostate were grown as previously described (Doles et al.,
2005). Experimental supplements included recombinant mouse NOGGIN (1 μg/
ml, R&D Systems, Minneapolis, MN), recombinant human BMP4 (300 ng/ml,
R&D Systems), octylated SHH (5 nM, Curis, Cambridge, MA), or cyclopamine
(10 μM; Toronto Research Chemicals, Toronto, Canada). Organ culture media
were replenished every 48 h.
Transgenic mice
A breeding pair of Noggintm1(Lacz)Am mice that was first described by the
McMahon lab (McMahon et al., 1998) was obtained with permission from
Brigid Hogan (Duke University). The LacZ open reading frame was targeted to
the first exon of Noggin and the remaining gene sequence, except for a small
portion of the 3′-terminus, was excised to generate the mutant allele. The
Noggin mutant mice described by McMahon were maintained on a C57BL6/J
background but are now out-crossed with ICR mice. LacZ primers (forward:
ACC CAA CTT AAT CGC CTT GC; reverse: AAC AAA CGG CGG ATT
GAC C) identified the genotype of the offspring. Noggin−/− tissue was obtained
frommale fetuses during in utero development or at day of birth. A breeding pair
of Gremlin+/− (Grem1tm1Rmh) mice that was first described by Khokha et al.
(2003) was provided with permission by Dr. Xin Sun (University of Wisconsin).
A breeding pair of Chordin+/− (Chrdtm1Emdr) mice was provided by the Edward
DeRobertis lab (UCLA) and was maintained on a mixed B6SJLF1/JxC57Bl/6J
background.
Renal grafts
UGS were dissected, cleaned, and seminal vesicles removed. The tissue was
stored in cold Hank's Buffer until surgical implantation under the renal capsule
of CD-1 nude male mice that were at least 8 weeks of age as described (http://
mammary.nih.gov/tools/mousework/Cunha001/index.html). After 3 weeks,
UGS grafts were removed from their hosts. For each host mouse, half of each
graft was fixed in 10% formalin for histology and the other half was snap frozen
for RNA analysis.
Scanning electron microscopy
E17 UGS specimens were partially digested with 1% trypsin in HBSS for
90 min at 4 °C. UGS epithelium was mechanically separated from UGS
mesenchyme then processed, mounted, and imaged by scanning electron
microscopy as described previously (Lin et al., 2003).
Immunofluorescence and immunohistochemistry
UGS and prostate tissue sections were de-paraffinized, hydrated, and
processed for antigen retrieval (Garrett, 1998). UGS sections were incubated for
overnight at room temperature in a blocking buffer containing anti-P63 rabbit
polyclonal antibody (1:100, Santa Cruz Biotechnology Inc., Santa Cruz, CA).
UGS sections were rinsed briefly and incubated for 1 h at RT with blocking
buffer containing Alexa Flour 546 or 488-conjugated goat anti-mouse IgG(1:200, Invitrogen). Sections were DAPI counterstained, cover-slipped, and
imaged. To visualize proliferating cells, 5-bromo-2′-deoxyuridine (BrdU)
labeling medium was added to the organ culture media (1:1000 v/v, Roche
Applied Science) 4 h prior to fixing the UGS tissue or injected (1ml undiluted per
100 g body weight, i.p.) into mice 2 h before euthanasia. BrdU-positive cells
were labeled according to the manufacturer's protocol. BrdU-positive proliferat-
ing cells (percent of total cells) were counted from 3 to 6 sections from each UGS
(4 UGS per genotype), using a fixed area from a 200× magnification field. To
examine the effect of BMP4 and NOGGIN on cell proliferation, 2 to 6 images,
and 13 to 51 ducts were identified in each of 16 UGSs (four UGSs per treatment
group). Within each duct, we counted the numbers of (P63+,BrdU+); (P63+,
BrdU−); (P63−,BrdU+); and (P63−,BrdU−) epithelial cells and calculated the
ratios P63+,BrdU+)/(P63+,BrdU−) and (P63−,BrdU+)/(P63−,BrdU−) to deter-
mine the mitotic index among P63+ and P63− epithelial cells, respectively. We
compared these ratios across treatment groups using an analysis of variance with
a random mouse effect to account for the repeated measurements taken from the
same animal. We used an arcsin-square-root transformation of the ratios in order
to better meet the assumptions of the analysis. Pair-wise comparisons were made
using Fisher's protected least significant difference tests when the overall
treatment effect was significant. P-values less than 0.05 were considered as
significant. All analyses were performed using SAS statistical software version
9.1, SAS Institute Inc., Cary, NC.Results
Localization of Noggin expression in the developing male UGS
and prostate
Abundance and localization of Noggin mRNA during
prostate development was determined by a combination of
real-time PCR, in-situ hybridization, and assessment of β-
galactosidase activity in Noggin+/− mice that expressed LacZ
under the control of the Noggin promoter. Noggin expression
was restricted to UGS mesenchyme, was most abundant prior to
the onset of prostatic budding (E14–E16), and then decreased
gradually during bud elongation (E17–P1) and postnatal
prostate morphogenesis (Fig. 1A). Mesenchymal Noggin
expression extended from the bladder neck through the UGS
and urethra at E14 (not shown) and E16 (Fig. 1B, left, top row).
Later in development, Noggin expression localized to a thin
band of mesenchyme peripheral to the nascent smooth muscle
layer. Noggin expression contoured nascent buds and its
expression domain around buds was expanded and concentrated
distally towards bud tips (Fig. 1B, middle row). Noggin
expression at P5 and P10 remained tightly associated with the
ductal network of the developing prostate (Fig. 1B, bottom
row). Noggin expression in the adult prostate was very low (not
shown).
Regulation of Noggin expression
To examine the influence of SHH and BMP4 on Noggin
expression, we utilized organ culture of the E14 male UGS in
DHT-supplemented, serum-free media. Exogenous BMP4
significantly increased Noggin expression (Fig. 2A). This
appears to be a direct effect on UGS mesenchyme since
BMP4 also induced Noggin expression in the UGSM-2 cells
(Fig. 2B). Noggin expression in the cultured UGS was
unchanged by the addition of exogenous SHH (Fig. 2A).
However, RT-PCR analysis of SHH-responsive Gli1 expression
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these cultured tissues in the absence of exogenous SHH and no
significant increase with SHH treatment (results not shown).
Since the effect of exogenous SHH on Noggin may be masked
by robust constitutive Hh signaling, we examined the effect of
the Hh inhibitor cyclopamine on Noggin expression (Fig. 2A).
Chemical blockade of Hh signaling by cyclopamine produced a
marked increase in Noggin mRNA abundance, suggesting that
Hh signaling actually represses Noggin expression. Since
studies examining the effect of Shh and cyclopamine on Nog-
gin expression in the UGSM-2 cell line revealed no direct
effects (not shown), we infer that the effect of Hh signaling on
Noggin expression may be context-dependent or require
crosstalk between the UGS epithelium and mesenchyme.Phenotype of developing mouse urogenital tract from Noggin−/−
male mouse fetuses is abnormal and unique from Chordin−/−
and Gremlin−/− male fetuses.
Noggin−/− mice have been previously reported to exhibit
stunted growth, lack of cranial fusion, shortened limbs, a
complete loss of lumbar skeletal and tail formation, and
perinatal lethality (McMahon et al., 1998; Smith, 1999).
However, development of the urogenital system in these mice
has not been previously described. In our study of male
Noggin−/− mouse fetuses, we observed a constellation of
urogenital abnormalities including an occasional pelvic kidney,
and variable degrees of cryptorchidism ranging from a high
intra-abdominal position to complete descent. Some males
exhibited agenesis of the membranous (pelvic) urethra, others
developed a precursor urethral epithelial tube, and some
exhibited agenesis of the bulbourethral gland. The most striking
abnormalities were incomplete separation of the hindgut from
the UGS and agenesis of the tail. Separation of the hindgut from
the UGS normally occurs at E13 when endodermal lined
mesenchymal Rathke folds, which flank the UGS laterally, fuse
medially to create the urorectal septum (Hynes and Fraher,
2004). Whereas E17 WT males exhibited a complete separation
of the UGS and hindgut, the E17 Noggin−/− male exhibited a
fistulous connection between the hindgut and the dorsal surface
of the UGS (Fig. 3A). This was typically associated with anal
atresia. The E17 Noggin−/− female exhibited a similar defect
(not shown).
Scanning electron microscopy was performed on E17
Noggin−/− and WT UGS tissues (n=3 per genotype) in which
the epithelium was mechanically separated from UGS
mesenchyme in order to provide high resolution imaging of
the ductal budding pattern. The isolated E17 WT UGSFig. 1. Temporal and spatial expression of Noggin in the developing UGS and
prostate of male mice. (A) To assess the temporal expression of Noggin during
prostate development, whole UGS from embryonic male mice and isolated
ventral prostate (VP), dorsolateral prostate (DLP), and coagulating gland (GC)
of postnatal male mice were collected at regular intervals during development
(E14–P10). RNAwas isolated from pooled UGS tissues (n=6–9 E14–E18 male
fetuses from multiple litters) or individual prostate tissues from P1 to P10 male
neonates. Noggin mRNA abundance was determined by real-time PCR and
normalized to glyceraldehyde phosphate dehydrogenase gene expression.
Results are the mean (±SEM) of two RNA pools for E14–E18 UGS, or three
separate prostates (P1–P10. (B) Temporal and spatial expression of the
Noggintm1(Lacz)Am transgene in developing UGS and prostate from Noggin+/−
transgenic mice. UGS or prostate tissues were removed from male mice at
different days during gestation and postnatal development and probed for
Noggintm1(Lacz)Am-mediated β-galactosidase activity or Noggin mRNA expres-
sion by whole-mount ISH. Photographs are representative of nN10 UGS
specimens. To visualize the global expression of Noggin as well as its
expression in specific prostate structures, β-galactosidase activity in UGS
specimens from P3 mice was visualized by whole-mount imaging (left, center
row), imaging of sagittal sections cut along the caudal-cranial urethral axis
(center, center row), and imaging of transverse sections cut along the lateral-
medial urethral axis (right, center row). Noggin expression was observed in
mesenchyme surrounding seminal vesicles and prostatic buds of the VP, DLP,
and CG in P1–10 mouse prostate. Noggin expression was most concentrated at
distal tips of individual nascent DLP buds and decreased proximally towards the
base of buds (right, center row).
Fig. 2. Regulation of Noggin expression in the UGS. (A) To assess the
regulatory relationship between NOGGIN, SHH, and BMP4, UGSs from E14
WT male mice were exposed in organ culture to recombinant octylated SHH
(5 nM), BMP4 (300 ng/ml), NOGGIN (1 μg/ml), the hedgehog inhibitor
cyclopamine (10 μM), or vehicle (0.1% BSA, control) for 3 days and the relative
abundance of Noggin mRNA was determined for individual cultured UGS
tissues by real-time RT-PCR. Results are mean (±SEM), n≥5 UGS specimens.
(B) To determine whether BMP4-mediated induction of Noggin mRNA was
caused by these agents acting directly on UGS mesenchyme, the UGSM-2 cell
line (Shaw et al., 2006) was exposed to vehicle (0.01% BSA) or recombinant
BMP4 for 24 h and the expression of Noggin mRNA mean (±SEM) was
evaluated by real-time RT-PCR from three independent experiments. Significant
differences between groups were determined by analysis of variance (ANOVA),
followed by the Fisher least significant difference post hoc test. ∗Indicates
significantly different from vehicle-exposed control UGS (pb0.01).
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formed by two ridges from which the dorsal UGS buds emerge
(Fig. 3B, dorsal buds are pseudo-colored green). Lateral
prostatic buds (yellow) emanated from the lateral surfaces
flanking the sulcus. The seminal vesicle (SV) and ductus
deferens (DD) drained into the ejaculatory duct located within
the dorsal sulcus and caudal to the prostatic utricle (PU). CG
buds (red) and VP buds (blue) were located cranial to the
ejaculatory duct. The bladder neck was positioned at a right
angle to the urethra and the VP, lateral, and CG buds formed at
discrete sites along the prostatic urethra immediately caudal to
its connection to the bladder neck (Fig. 3B, right, top row). The
E17 Noggin−/− UGS appeared somewhat smaller and exhibited
several distinctive abnormalities. The characteristic dorsal
ridges were absent or reduced in size, resulting in loss of the
dorsal sulcus and exposure of the ejaculatory duct connection.
The angulation of the bladder neck–urethral axis was
considerably more obtuse. Most striking was the total absence
of VP and CG buds in all three Noggin−/− UGS samplesexamined (Fig. 3B, right, bottom row). The number of dorsal
and lateral buds was also reduced but a complete absence of
ductal budding was not observed in any of the Noggin−/− UGS
specimens.
Two other BMP antagonists, Gremlin and Chordin, are also
expressed in the UGS during prostatic bud initiation (results not
shown). In contrast to Noggin, however, they do not appear to
play an essential role in normal prostatic budding. When we
examined Gremlin−/− and Chordin−/− mice several days after
prostatic bud initiation (Fig. 3C), the budding patterns and
bladder neck–urethra angle appeared indistinguishable from
WT male littermates.
To exclude the possibility or occult hypogonadism in the
Noggin−/− mouse, we utilized previously described functional
assays of testis androgen production (Donjacour et al., 2003).
First, E15–E16 WT and Noggin−/− UGS tissues were cultured
together with their respective testes in (−) DHT, serum-free
organ culture for 7 days. The UGS tissues exhibited comparable
degrees of budding, indicating sufficient androgen production
by the Noggin−/− to induce budding. Second, the WT P1
prostate was cultured in androgen-free, serum-free organ culture
alone or together with WT or Noggin−/− testes. WT tissues
cultured alone showed minimal branching; whereas, the tissues
cultured with WT and Noggin−/− exhibited similar degrees of
branching morphogenesis (Supplemental Fig. 1).
Noggin is required for formation of the ventral mesenchymal
pad and for ventral UGS epithelial cell proliferation
Signals from UGS mesenchyme play an integral role in
initiating androgen-dependent prostatic buds from the UGS
epithelium. UGS mesenchyme is thought to possess regionally
patterned inductive capacities that determine the identity of the
different prostate lobes and induce epithelial proliferation and
bud initiation (Hayashi et al., 1993). Abnormal UGS mesench-
ymal development is one possible mechanism for deficient bud
formation in Noggin−/− UGS. Consistent with this hypothesis,
we observed a reduction in ventral mesenchyme thickness and
density in P1 Noggin−/− prostate tissue sections (Fig. 4A, left
column, outlined in pink). Decreased volume or possible
agenesis of the ventral mesenchymal pad, a specialized UGS
mesenchymal tissue compartment that is responsible for
synthesis of FGF10 and other prostatic bud-inducing secretory
proteins, may contribute to impaired epithelial cell proliferation
and prostatic bud initiation.
Two days prior to prostatic bud initiation, the E14
Noggin−/− UGS showed diminished ventral mesenchymal
cell density relative to the age-matched WT UGS (Fig. 4A,
right column, outlined in pink), which is consistent with
impaired ventral mesenchymal pad formation observed on P1.
The decreased ventral mesenchymal cell density at E14 was
accompanied by a significant decrease in ventral UGS
epithelial cell proliferation (Fig. 4B, white arrowheads).
These results indicate that unopposed BMP signaling may
inhibit formation of the ventral mesenchymal pad and
proliferation of ventral epithelium, thereby blocking ventral
prostatic bud formation.
Fig. 3. Phenotype of the developing prostate from Noggin−/−male mouse fetuses. (A) UGS/hindgut complexes fromWTand Noggin−/−male mice were removed from
representative E17 male mouse fetuses (n=3 per genotype) and visualized by light microscopy. The urogenital division (UD) that separates the hindgut (HG) from the
UGS in the WT specimen was absent (denoted by “∗”) and the membranous portion of the urethra (MU) failed to elongate in the Noggin−/− mouse specimen. (B) To
better visualize the overall architecture of the Noggin+/+ and Noggin−/− UGS, UGS epithelium (UGE) was separated from mesenchyme and visualized by scanning
electron microscopy (SEM). Isolated UGE of a representative WT E17 male fetus (n=3) revealed seminal vesicles (SV) and ductus deferens (DD) that drained into the
ejaculatory duct located within the dorsal sulcus (white arrowhead), or groove, created by two prominent dorsal ridges (DR) on the lateral surfaces of the UGS.
Emerging VP (blue), dorsal (green), lateral (yellow), CG (red) buds, and the prostatic utricle (PU) were also evident. On the other hand, VP buds and the PU were
missing, DLP and CG budding were reduced, and the ejaculatory ducts were laterally displaced and drained into the DR instead of the dorsal sulcus (∗) in the
representative Noggin−/− UGS. Also, the angle between the bladder neck and urethra of WT UGS approximated 90°, whereas this angle was closer to 160° in the
Noggin−/− UGS. (C) SEM images of Gremlin−/− and Chordin−/−male mouse prostate at P1 reveal budding patterns and prostate architecture that is very similar to WT
littermates.
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male mice
The absence of ventral buds and the ventral mesenchymal
pad in the Noggin−/− UGS could reflect either altered patterning
in lobar development, resulting in a true loss of VP deter-mination, or an altered morphology of the UGS with VP identity
shifted to a more dorsal position. Since the different lobes of the
prostate are distinguished by the expression of lobe-specific
markers, we sought to distinguish between these two possibi-
lities by examining lobe-specific gene expression in mature
prostate tissue of the Noggin−/− mutant. To circumvent the
Fig. 4. Noggin is required for formation of the ventral mesenchymal pad and for
ventral UGS epithelial cell proliferation. (A, left column) Representative H&E-
stained prostate tissue sections (n=5 per genotype) of P1 mouse prostate
indicating thinning or absence of the ventral mesenchymal pad (VMP) in the P1
Noggin−/− prostate. (A, right column) E14 WTand Noggin−/− UGS were labeled
in utero with BrdU 2 h prior to euthanasia, sectioned and stained to evaluate
epithelial cell proliferation. Representative photomicrographs (n=3 UGS per
genotype) from WT and Noggin−/− UGS reveals decreased ventral UGS
mesenchymal cell (UGM) density (outlined in pink) and fewer proliferating
ventral UGS epithelial cells (UGE; white arrowheads), while cell proliferation in
the Wolffian-derived epithelium (WE) was comparable between groups. (B)
Proliferating ventral UGS epithelial cells (% of total) were quantified from a
fixed area within 3–6 sections per UGS (3 UGS per genotype). Results are
expressed as mean (±SEM), n=3. Significant differences between groups were
determined by Student's T test. ∗Indicates significantly different from WT
(pb0.05). Scale bar=100 μm.
223C. Cook et al. / Developmental Biology 312 (2007) 217–230limitations of perinatal lethality in Noggin−/− mice and
examine the requirement of Noggin for prostate development
during early postnatal life, P1 WT and Noggin−/− male
prostates were grafted under the renal capsule of adult male
nude mice. The 3-week grafts were similar in size even though
the P1 Noggin−/− prostate was approximately half the size of
the WT prostate at the time of grafting. Histological
examination of sectioned grafts from both genotypes revealed
glandular morphogenesis consistent with prostatic differentia-
tion (Fig. 5A); however, the Noggin−/− grafts were notable for
the absence of any glands showing the characteristic VP
glandular architecture. Real-time PCR was performed on
mRNA from the grafts to assess relative abundance of
prostatic differentiation markers. The specificity of spermine
binding protein (Sbp) as a marker for VP, renin 1 (Ren1) for
CG, and probasin (Pbsn) for DLP was confirmed using cDNA
isolated from the various lobes of the P35 WT mouse prostate
(Fig. 5B). Expression of the DLP (Pbsn) and CG (Ren1)
markers in Noggin−/− grafts was not significantly different
from WT grafts (Fig. 5B). However, expression of the VP-
specific marker (Sbp) (Lin et al., 2003; Mills et al., 1987;
Thielen et al., 2007) was absent from the Noggin−/− grafts.
In order to determine whether VP development in the
Noggin−/− UGS could be rescued by exposure to exogenous
NOGGIN prior to and during initiation of prostatic budding, E12
WTandNoggin−/−UGSwere exposed to recombinant NOGGIN
protein for 5 d in organ culture and grafted under the renal
capsule for 21 d. Although UGS fromWT mice were capable of
forming ventral prostate tissue under these conditions, recombi-
nant NOGGIN protein was unable to rescue ventral prostate
development in Noggin−/− UGS (results not shown).
To determine whetherNoggin haploinsufficiency would exert
a ventral lobe-specific effect on postnatal prostate development,
we compared prostate lobe size, histological appearance and
branching complexity in WT and Noggin+/− mice. The VP
weight from P35 Noggin+/− male mice was significantly less
than that of age-matched WT controls and there was no
difference in the DLP or CGweights (Fig. 5C). Micro-dissection
of the different prostatic lobes showed no significant differences
between WT and Noggin+/− mice in the number of main ducts,
branch points, or duct tips for any of the lobes and histological
examination of each prostate lobe of adult Noggin+/− mice
revealed no obvious abnormalities (results not shown).
Effect of NOGGIN on budding
In order to determine the role of NOGGIN in prostatic
budding, E14 UGS tissue was cultured for 7 days in DHT-
supplemented control media or in media containing DHT and
exogenous NOGGIN, BMP4, or both. Prostatic main ducts and
bud tips were quantitated from light micrographs (Fig. 6) as
described previously (Lamm et al., 2001). NOGGIN exposure
alone did not significantly alter the number ofmain prostatic ducts
or bud tips compared to control UGS tissues and although
NOGGIN appeared to increase outgrowth of buds in several
different experiments, this difference was not amenable to
quantitative analysis. As previously reported, BMP4-exposed
Fig. 5. Ventral prostate development is inhibited in Noggin−/−male mice. To determine if UGSs from Noggin−/−male mice are capable of supporting development and
differentiation into mature prostate tissue, prostates from WT, Noggin+/−, and Noggin−/− P1 newborn mice were grafted under the kidney capsule of nude mice for
21 days. (A) Hematoxylin- and eosin-stained graft sections of WT and Noggin−/−mice revealed a ductal network characteristic of mature prostate containing prostatic
secretions. There were no qualitative differences in the dorsolateral prostate ductal structure of WT and Noggin−/− UGS renal grafts. Scale bar=100 μm. (B) Prostate
lobe-specific marker abundance was compared between the WT and Noggin−/− prostate renal grafts. Results are expressed as mean (±SEM), n=3. Significant
differences between groups were determined by Student's T test. ∗Indicates significantly different from WT (pb0.05). Specificity of Sbp, Ren1, and Pbsn expression
for VP, CG, and DLP, respectively, was established by comparing the relative mRNA abundance of each message in prostate tissue from P35 WT mice. Results are
expressed as mean (±SEM), n=3. Significant differences between groups were determined by ANOVA followed by the Fisher least significant difference post hoc test.
†Indicates significantly different from VP, CG, and DLP for Sbp, Ren1, and Pbsn, respectively (pb0.05). Significant differences between groups were determined by
Student's T test. (C) To determine whether Noggin+/− mice exhibited a haploinsufficient phenotype, P35 WT and Noggin+/− prostate lobe weights for were measured
and normalized to total body weight. Results are mean (±SEM), n≥18 for each genotype. ∗Indicates significantly different from WT (pb0.05).
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et al., 2005; Lamm et al., 2001) and concurrent exposure to
NOGGIN+BMP reversed bud inhibitory actions of BMP4.
Ontogeny of P63 during prostate ductal morphogenesis
While prostate ductal morphogenesis has been extensively
studied, the ontogeny of P63 expression during prostate
development and its relationship to epithelial proliferation and
ductal outgrowth has not been well characterized. P63 isrequired for prostatic bud development, may be expressed by
precursors of differentiated secretory cells and is expressed by
basal cells of the adult prostate (Signoretti et al., 2005). Prior to
the onset of prostate ductal budding, P63 was expressed
throughout the multilayered epithelium of the UGS, with
stronger staining at the epithelial-mesenchymal interface (Fig.
7A). During ductal budding, the nascent epithelial buds
exhibited a nearly continuous sheath of P63+ cells at the
epithelial–mesenchymal interface that surrounded a core of
P63− epithelial cells (Fig. 7B). Later in development, the
Fig. 6. Effect of NOGGIN on prostatic budding, branching, and cell proliferation in UGS or neonatal prostate organ culture. To determine whether exposure to
recombinant NOGGIN and/or recombinant BMP4 alters prostatic budding or E14WT UGS was incubated for 7 days in organ culture containing vehicle (0.01% BSA;
control), recombinant BMP4 (300 ng/ml), recombinant NOGGIN (1 μg/ml), or a combination of NOGGIN and BMP4. (A) The number of bud tips (□) and main ducts
(●) per UGS was determined. Results are mean (±SEM), n≥10 samples per group. Significant differences between groups were determined by ANOVA, followed by
the Fisher least significant difference test. ∗Indicates significantly different from control (pb0.001). Representative UGS samples after 7 days in organ culture are
shown for each treatment group.
225C. Cook et al. / Developmental Biology 312 (2007) 217–230continuous sheath of P63+ cells persisted at duct tips but was
discontinuous in elongating bud stalks and assumed a punctate
basal epithelial distribution more characteristic of adult prostate
ducts (Figs. 7C, D). Double immunofluorescence staining for
P63 and ki67 was performed to examine co-localization of P63+
cells with the proliferating cell population during ductal
outgrowth. High magnification imaging of the buds in the P1
prostate showed P63+ cells lining the periphery of emerging
buds (Fig. 7E, red staining) and active cell proliferation in bud
epithelium and surrounding mesenchyme (Fig. 7E, Ki67 green
staining). Ki67 expression co-localized with P63+ cells at the
distal tips of emerging buds (Fig. 7E, yellow double staining).
P63+ cells in the proximal portion of buds were mitotically
quiescent and proliferation was instead restricted to P63− cells
in the periphery and center of non-canalized proximal segments.
NOGGIN stimulates a burst of proliferation in P63+ UGS
epithelial cells following BMP4 exposure in UGS organ culture
To investigate how NOGGIN influenced the distribution of
proliferating cells, P1 prostate tissue was cultured in DHT-
supplemented media for 4 days±addition of NOGGIN on day 3.
Tissues were incubated with BrdU 4 h prior to fixation to label
mitotically active cells. P63+ and BrdU+ cells were identified by
immunohistochemistry and quantified as described in the
Materials and methods. Control tissues displayed epithelial
cell proliferation generally, concentrated toward the periphery of
the tissue and localized primarily to bud tips. These proliferating
cells included P63+ and P63− cells and the proliferation pattern
was similar to that observed in vivo at P1. Preliminary studies
showed that treatment with NOGGIN for 4 days in organ culture
produced no obvious change in epithelial proliferation (unpub-lished observations). Recognizing that reciprocal regulatory
relationships between Bmp4 and Noggin or functional redun-
dancy provided by other members of the BMP/NOGGIN family
may frustrate our efforts to tease out the effect of the BMP4/
NOGGIN axis on epithelial proliferation, we examined the
influence of short-term NOGGIN exposure on epithelial
proliferation following pre-treatment with BMP4. P63+ cells
were localized to the outer edge of elongating ducts in prostate
tissues that were cultured for 4 days in control media, and
BrdU+ proliferating cells were observed in both mesenchymal
and epithelial tissue compartments (Fig. 8A). When tissues were
cultured in control media for 3 days followed by treatment with
NOGGIN for 1 day (Fig. 8B), there was no change in
proliferation of either P63+ or P63− cells compared to control
tissues. Tissues cultured in the presence of exogenous BMP4 for
4 days exhibited significantly decreased proliferation of P63+
epithelial cells (Figs. 8C and E) but no change in the proliferation
of p63− cells (data not shown). When tissues were treated for
3 days with BMP4 followed by treatment with NOGGIN for
1 day, there was an apparent burst of P63+ epithelial
proliferation at the leading edge of the buds and ducts (Fig.
8D) and statistical analysis demonstrated that 1 day of NOGGIN
treatment restored P63+ cell proliferation to control levels (Fig.
8E). There was no change in the proliferation in P63− cells (data
not shown). These observations suggest that opposing actions of
BMP4 and NOGGIN converge to regulate proliferation of P63+
epithelial cells in the nascent ducts of the developing prostate.
Discussion
NOGGIN is an extracellular binding protein with high
affinity for BMP4 and lesser affinity for BMP2, BMP7, and
Fig. 7. Ontogeny of P63 expression in developing WT UGS and early postnatal prostate. CD-1 mouse UGS and prostate tissue specimens were analyzed for P63
expression by immunohistochemistry. (A) Multiple layers of P63-positive staining basal epithelial cells accumulated beneath the basal lamina (partially contoured in
white) of the UGS and urethra at E16 in WTmale mice. (B–E) During postnatal development from P1 to P10, P63 expression was gradually restricted to a single P63+
epithelial cell layer beneath the basal lamina of developing prostate ducts. (E) Immunohistochemical analysis of P63 and Ki67 expression in prostate sections from P1
WT male newborn mice revealed numerous P63+ basal epithelial cells (red) throughout prostatic epithelium, including prostate buds. Ki67-positive cells (green) were
observed in prostatic mesenchyme and prostate epithelium. P63+, proliferating cells (yellow) in prostate epithelium were restricted to the tips of emerging prostate
buds (arrowheads). Scale bar=100 μm.
226 C. Cook et al. / Developmental Biology 312 (2007) 217–230GDF5 (Balemans and Van Hul, 2002). Both Bmp4 and Bmp7
are abundantly expressed during prostate development while
Bmp2 is expressed at lower levels and Gdf5 expression is
virtually undetectable (Grishina et al., 2005; Lamm et al., 2001).
Both Bmp4 and Bmp7 are expressed in the periurethral
mesenchyme prior to bud formation (Grishina et al., 2005;
Lamm et al., 2001). Once the prostate buds have formed, Bmp4
expression is most abundant in the mesenchyme surrounding the
proximal duct segment. Bmp7 expression is diminished in the
UGS mesenchyme surrounding prostatic bud tips while being
increased in bud epithelia. Both have been shown to inhibit
budding/branching in organ culture and the action of BMP4 has
been linked to a selective inhibition of epithelial proliferation.SMAD1 phosphorylation is a downstream marker for BMP
receptor activation. Grishina et al. (2005) observed that
phosphorylated SMAD1 expression was restricted to mouse
urogenital sinus epithelium at E18, suggesting that the effect of
the BMP ligands is a direct effect upon UGS epithelium.
Supporting this inference are preliminary findings that expres-
sion of phosphorylated SMADs 1, 5, and 8 and the BMP4-
responsive gene, Smad6, are largely confined to the urogenital
sinus epithelium (unpublished observations).
BMP4 regulates budding and branching morphogenesis in
the developing lung by increasing expression of the cell cycle
inhibitor P21 and decreasing expression of Cyclin D and Cdk2
(Jeffery et al., 2005). BMP7 is reported to control formation of
Fig. 8. NOGGIN exposure induces proliferation of BMP4-exposed prostate in organ culture. P1 prostates were incubated for 3 days in organ culture with vehicle (0.1%
BSA; control) or recombinant BMP4 (300 ng/ml). The organ culture media was then replaced with media containing vehicle, recombinant NOGGIN (1 μg/ml), or
BMP4 and cultures were incubated for an additional day. Four hours before harvesting the tissue, BrdU was added to the media to stain proliferating cells. Tissue
sections were then assayed for BrdU (green) and P63 (pink) expression by IHC. Prostatic buds are indicated by arrowheads and the basal lamina for one bud in panels
A–D is traced in white. (A) Vehicle-exposed prostates showed proliferation in prostate mesenchyme and P63+ and P63− epithelial cells. (B) NOGGIN (NOG)
exposure for 1 day does not change the proliferation of P63− epithelial cells within the core of prostatic buds compared to control prostates. (C) BMP4 exposure for
4 days decreased proliferation of P63+ but not P63− epithelial cells compared to control. (D) BMP4 exposure for 3 days followed by NOGGIN exposure for 1 day
caused a burst of proliferation in P63+ but not P63− epithelial cells at the leading edge of ducts. Scale bar=100 μm. (E) Mitotic indices for P63+ cells were calculated
by counting the number of proliferating, BrdU- and P63-positive cells as a fraction of the total P63+ cell population for each treatment group. Results are the mean
(±SEM) of 2 to 6 sections from each of four UGS specimens per treatment group. Differences between groups were determined by Fisher's protected least significant
difference test. ∗Indicates significantly different from control (pb0.05). Analysis of mitotic indices for P63− cells revealed no differences between any of the treatment
groups (not shown).
227C. Cook et al. / Developmental Biology 312 (2007) 217–230new buds and branching morphogenesis in the prostate by
regulating Hes1/Notch1 expression domains (Grishina et al.,
2005). Our studies lead us to postulate that NOGGIN acts to
specifically inhibit BMP4/7 activity during ductal budding and
at the distal tips of elongating prostatic buds to facilitate
outgrowth and simultaneously create a gradient of BMP
signaling along the ductal axis. These activities are suggested
by our organ culture studies showing that exogenous NOGGINexpands proliferation of P63− cells specifically at the distal tips
of developing prostatic buds and can reverse BMP4-induced
inhibition of bud outgrowth. These effects of NOGGIN may be
mediated by regulation of cell cycle genes and regulation of
Hes1/Notch 1 expression.
In the lung, where BMP signaling has been linked to axial
patterning of epithelial proliferation and differentiation of the
developing bronchiole (Weaver et al., 2000), Noggin and Bmp4
228 C. Cook et al. / Developmental Biology 312 (2007) 217–230expression have been correlated with inductive signaling by
SHH (Weaver et al., 2003) and within the context of the
developing prostate duct, Shh and Noggin expression do occur
in apparently complementary patterns. Epithelial Shh expres-
sion was concentrated at the duct tip while mesenchymal
Noggin expression was concentrated in UGS mesenchyme
around the duct tip. While suggestive of an inductive relation-
ship, we have been unable to show a direct inductive effect. We
could not demonstrate a direct effect of SHH on Noggin
expression in UGSM-2 cells (unpublished observations) nor
could we show a change in Noggin expression in SHH-treated
UGS cultured in vitro. In fact, we observed a surprising increase
in Noggin expression when the cultured UGS was treated with
the hedgehog inhibitor cyclopamine. These observations do not
exclude an interdependency of Shh and Noggin expression but
argue against a simple, direct inductive relationship. In contrast,
BMP4 does exert a clear inductive effect on Noggin expression.
This was demonstrated in both UGS organ culture and in a UGS
mesenchymal cell-based assay, arguing that this is a direct effect
of BMP4 on UGS mesenchyme that does not require crosstalk
between mesenchyme and epithelium. Similar inductive
relationships have been observed in other systems (Nakamura
et al., 2005; Pujades et al., 2006; Stottmann et al., 2001). The
complementary gradients of mesenchymal Bmp4 and Noggin
expression along the duct axis could result from inductive
interactions superimposed on the physical displacement asso-
ciated with bud outgrowth. Alternatively, it could suggest that
the inductive relationship is modified by other factors such as
SHH or FGF10.
We expected that Noggin loss of function would incur
significant disruptions of epithelial proliferation and differentia-
tion during development in vivo. We were therefore very
surprised by the preservation of ductal architecture and
epithelial cell populations in rescued grafts of the Noggin−/−
UGS. It is possible that the perturbations introduced by Noggin
loss of function are muted by compensatory changes in Bmp
ligand expression and/or altered expression of other inhibitory
ligands such as Gremlin that provide a measure of functional
redundancy (Merino et al., 1999). Indeed, we have recently
demonstrated that Shh loss of function is mitigated, in part, by
functional compensation achieved through increased expression
of Ihh (Doles et al., 2006). In an effort to circumvent these
issues, we used shorter-term culture and a pulse-chase strategy
to dissect out the influence of NOGGIN on prostatic budding
and proliferation in UGS organ culture. These studies clearly
showed that BMP4 specifically inhibited the proliferation of
P63+ cells concentrated at the tips of nascent prostatic buds and
that this effect is completely reversed by NOGGIN. These
studies complement our finding that inhibition of ductal
budding by exogenous is similarly blocked by NOGGIN and
leads us to postulate that NOGGIN acts to specifically inhibit
BMP4/7 activity during ductal budding and promote P63+ cell
proliferation at tip of the nascent duct to facilitate outgrowth and
simultaneously create a gradient of BMP signaling along the
ductal axis. The lack of proliferation effect of NOGGIN
exposure for 1 day without BMP4 pre-treatment suggests that
endogenous BMP activity has already been neutralized byendogenous BMP–antagonist activity, an activity consistent
with the concentrated expression of Noggin around the growing
duct tip.
Noggin−/− mice exhibit specific abnormalities of prostate
development including generalized deficiency of prostatic buds
and specific loss of VP development. Since exogenous BMP4
or BMP7 added to UGS and prostate organ cultures caused a
global dose-dependent reduction in prostatic buds (Grishina et
al., 2005; Lamm et al., 2001), the generalized deficiency of
prostatic budding is likely caused by unopposed BMP signaling
from the actions of BMP4 and BMP7. Against a generalized
inhibition of ductal budding, the loss of VP development in the
Noggin−/− mutant appears to be a uniquely specific effect. Not
only was there complete loss of ventral budding in all mutants
examined, but there was deficiency or absence of the ventral
mesenchymal pad. The absence of the ventral mesenchymal pad
correlates with a deficit in proliferation in the ventral epithelium
at E14. Since the lobe specificity of epithelial differentiation is
determined by the identity of the inductive mesenchyme, the
absence of ventral mesenchyme explains the complete absence
of VP differentiation in rescued null grafts. This contrasts with
the observed absence of morphologically identifiable CG buds
but the unequivocal presence of CG differentiation marker
expression in the grafted tissues. While the Noggin−/− UGS was
approximately half the size of the WT UGS at E14, the renal
grafts were of roughly equal size. One possible explanation is
that the absence of Noggin alters patterning of the UGS
mesenchyme and lobar identity but does not change the overall
growth potential of the prostate. An alternative explanation is
that Nogginmay be expressed by the host mouse at the graft site
and provide functional compensation. In fact, we have shown
that Noggin is expressed by host stromal cells in LNCaP
xenograft tumors and is up-regulated by Shh overexpression
(unpublished observations).
Axial development of the male accessory sex organs
follows a sequential cascade from cranial to caudal (Altmann
and Brivanlou, 2001; Kmita and Duboule, 2003; Podlasek et
al., 1999a,b; Warot et al., 1997). Since the VP is the most
caudal structure of the prostate, one possible explanation for
VP agenesis in Noggin−/− mice is that unopposed BMP
signaling in the developing fetus causes generalized caudal
agenesis. We considered the possibility that VP agenesis is not
a prostate lobe-specific effect but rather a manifestation of
generalized caudal agenesis that affects the VP specifically
because it is the most caudal of the prostate lobes. Although
we did observe diminished proliferation in the ventral
mesenchyme of the Noggin−/− mutant, we do not favor this
interpretation because the uniform absence of the ventral
prostate in all KO's examined contrasts with the inconsistent
agenesis of even more caudal urogenital structures such as the
membranous urethra or bulbourethral gland. This suggests
some specificity in the effect on the VP beyond its relative
caudal position. A selective effect on VP development could
result if there is functional compensation for loss of Noggin in
the other regions of the UGS or greater BMP expression in the
ventral region compared to other regions of the UGS.
Alternatively, VP agenesis could result from an altered
229C. Cook et al. / Developmental Biology 312 (2007) 217–230patterning of the UGS if NOGGIN-mediated neutralization of
BMP activity is required to specify development of the ventral
mesenchymal pad and pattern ventral budding The failure to
restore VP development by in vitro organ culture with
exogenous NOGGIN may indicate that NOGGIN's role in
VP determination occurs prior to E12 or that proper
specification of VP development requires localized NOGGIN
activity that cannot be mimicked by addition to the media.
Recently, Bmp4 haploinsufficiency was shown to partially
rescue lung development in Noggin−/− mice suggesting that
the balance of BMP/NOGGIN activity is a critical regulator of
cell proliferation and differentiation (Que et al., 2006). It is
possible that a similar rescue of VP prostate could be obtained
by haploinsufficiency for Bmp4 and/or Bmp7. However, VP
determination appears to be influenced by a multiplicity of
factors, including members of the Hox gene family, retinoic
acid, and aryl hydrocarbon receptor ligands and it is possible
that the effect of NOGGIN loss of function occurs from
upstream effects on these other pathways as well as direct
effects on VP mesenchyme proliferation.
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